Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd. - Common Shares (NQ: ROIV )

11.12 +0.22 (+2.07%)
Streaming Delayed Price Updated: 3:26 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Roivant Sciences Ltd. - Common Shares

< Previous 1 2 Next >
Roivant Announces Redemption of Outstanding Warrants
From Roivant Sciences
Via GlobeNewswire
Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease
From Roivant Sciences
Via GlobeNewswire
Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program
Joining Adobe, Spotify, Nvidia, Morgan Stanley, and many others 
From Roivant Sciences
Via GlobeNewswire
UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023
From Roivant Sciences
Via GlobeNewswire
Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period
From Roivant Sciences
Via GlobeNewswire
Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis
From Roivant Sciences
Via GlobeNewswire
Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old
From Roivant Sciences
Via GlobeNewswire
Lokavant Hires Experienced Leaders to Accelerate Growth Trajectory
From Lokavant
Via Business Wire
Lokavant Emerges from Roivant Sciences with Multiple Industry Partnerships to Accelerate Impact on Clinical Research
From Lokavant
Via Business Wire
Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients
From Covant Therapeutics
Via GlobeNewswire
Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
From Roivant Sciences
Via GlobeNewswire
Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis
From Roivant Sciences
Via GlobeNewswire
Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs
PVTX-321 and PVTX-405 Achieve Development Candidate Nomination 
From Roivant Sciences
Via GlobeNewswire
Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement
From Roivant Sciences
Via GlobeNewswire
Roivant Sciences Announces Change to its Board of Directors
From Roivant Sciences
Via GlobeNewswire
Roivant Sciences Reports Financial Results for the Third Quarter Ended December 31, 2022 and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares
From Roivant Sciences
Via GlobeNewswire
Roivant Sciences Announces Proposed Public Offering of Common Shares
From Roivant Sciences
Via GlobeNewswire
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2022 on Monday, February 13, 2023
From Roivant Sciences
Via GlobeNewswire
Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both the Overall and the Biomarker
From Roivant Sciences
Via GlobeNewswire
Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases
From Roivant Sciences
Via GlobeNewswire
Roivant Sciences Reports Financial Results for the Second Quarter Ended September 30, 2022 and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Affivant to Present Data on AFVT-2101 at 37th Annual Meeting of SITC
From Roivant Sciences
Via GlobeNewswire
Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering
From Roivant Sciences
Via GlobeNewswire
Roivant Sciences Announces Proposed Public Equity Offering
From Roivant Sciences
Via GlobeNewswire
Roivant Sciences to Report Financial Results for the Second Quarter Ended September 30, 2022 on Monday, November 14, 2022 and Present at Upcoming Conferences
From Roivant Sciences
Via GlobeNewswire
Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
From Pfizer Inc.
Via Business Wire
Roivant Discovery Announces 2021 Open Science Fellows
From Roivant Discovery
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.